NovoCure (NVCR) Projected to Post Earnings on Thursday

NovoCure (NASDAQ:NVCR) is expected to be releasing its earnings data before the market opens on Thursday, February 27th. Analysts expect NovoCure to post earnings of ($0.34) per share and revenue of $161.30 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

NovoCure Trading Down 3.8 %

NASDAQ NVCR opened at $21.24 on Tuesday. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt-to-equity ratio of 0.27. The stock’s 50-day simple moving average is $26.44 and its two-hundred day simple moving average is $21.40. NovoCure has a twelve month low of $11.70 and a twelve month high of $34.13. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -15.17 and a beta of 0.62.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NVCR. Evercore ISI raised NovoCure from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $18.00 to $30.00 in a report on Monday, December 2nd. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of NovoCure in a research note on Tuesday, January 14th. Wedbush reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of NovoCure in a research note on Monday, January 13th. Finally, Piper Sandler increased their target price on shares of NovoCure from $28.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $32.67.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.